Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02674763 · ClinicalTrials.gov registry record · Phase 1
Open-label Study of IMGN779 in Adult Patients With Relapsed/Refractory CD33-positive Acute Myeloid Leukemia
A Phase 1 study, sponsored by ImmunoGen.
- Completed
- Registry status
- Phase 1
- Development phase
- 62
- Enrollment target
NCT02674763 is a Phase 1 study that has completed, run by ImmunoGen. The registered enrollment target is 62 participants.
The verdict
NCT02674763, a Phase 1 study, has completed, sponsored by ImmunoGen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 62 participants
- Enrollment target
Study Summary
This is an open label, multicenter Phase 1 study to determine the MTD, dosing schedule and RP2D of IMGN779 when administered as mono-therapy to adult AML patients with CD33 -positive disease.
Interventions
- DRUG IMGN779
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2016-03 |
| Est. Completion | 2019-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02674763
The ClinicalTrials.gov registry entry for NCT02674763 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 62 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ImmunoGen, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which IMGN779 is the first listed.
NCT02674763 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02674763 about?
NCT02674763 is a clinical study titled "Open-label Study of IMGN779 in Adult Patients With Relapsed/Refractory CD33-positive Acute Myeloid Leukemia". This is an open label, multicenter Phase 1 study to determine the MTD, dosing schedule and RP2D of IMGN779 when administered as mono-therapy to adult AML patients with CD33 -positive disease.
What is the current status of trial NCT02674763?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 62 participants. The study started on 2016-03. Estimated completion is 2019-07.
What interventions are being tested in trial NCT02674763?
The interventions under investigation include: IMGN779 (DRUG).
Who is sponsoring clinical trial NCT02674763?
This trial is sponsored by ImmunoGen, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.